IntelGenx Technologies Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IGX.TO research report →
Companywww.intelgenx.com
IntelGenx Technologies Corp. , a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health.
- CEO
- Dwight Gorham
- IPO
- 2008
- HQ
- Montreal, QC, CA
Price Chart
Valuation
- Market Cap
- $41.92M
- P/E
- -2.99
- P/S
- 28.58
- P/B
- -2.42
- EV/EBITDA
- -5.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -66.79%
- Op Margin
- -913.47%
- Net Margin
- -955.44%
- ROE
- 126.70%
- ROIC
- -291.67%
Growth & Income
- Revenue
- $1.04M · 9.37%
- Net Income
- $-9,927,000 · 7.14%
- EPS
- $-0.06 · 12.48%
- Op Income
- $-9,491,000
- FCF YoY
- 31.49%
Performance & Tape
- 52W High
- $0.30
- 52W Low
- $0.14
- 50D MA
- $0.23
- 200D MA
- $0.21
- Beta
- 2.54
- Avg Volume
- 19.27K
Get TickerSpark's AI analysis on IGX.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IGX.TO Coverage
We haven't published any research on IGX.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IGX.TO Report →